The study titled “Curcumin Supplementation as a Preventive Strategy Against Tamoxifen-Induced Nonalcoholic Fatty Liver Disease in ER+ Breast Cancer Patients: A Triple-Blind Randomized Placebo-Controlled Trial” demonstrated several positive outcomes. Notably, only 13.6% of patients receiving curcumin experienced an increase in NAFLD grade, compared to 54.5% in the placebo group, indicating that curcumin significantly slowed liver disease progression. Additionally, the occurrence of moderate to severe NAFLD (grade 2 or higher) was lower in the curcumin group (13.6%) versus the placebo group (40.9%), suggesting curcumin’s effectiveness in reducing advanced liver disease stages. Importantly, no adverse effects related to curcumin were reported, highlighting its safety profile in this context. These findings suggest that curcumin supplementation may serve as a protective measure against tamoxifen-induced NAFLD in ER+ breast cancer patients.
Source: https://www.tandfonline.com/doi/full/10.1080/19390211.2025.2465412
